We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

By LabMedica International staff writers
Posted on 17 May 2023
Print article
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints in laboratory workflows and staffing can lead to delays in providing test results to physicians and patients. A new pair of hematology analyzers now addresses these issues by offering user-friendly interfaces and the ability to connect multiple analyzers, effectively eliminating workflow bottlenecks and delivering the fast processing times needed in high-volume labs. These analyzers also offer integrated rules-based testing, which allows lab technicians of varying experience levels to interpret complex patient results and respond promptly.

Siemens Healthineers (Erlangen, Germany) has introduced two novel solutions for high-volume hematology testing, the Atellica HEMA 570 Analyzer and the Atellica HEMA 580 Analyzer. The complete blood count (CBC), a vital component of patient care, is one of the most frequently conducted diagnostic tests in the lab and often provides the first sign of a patient's illness. Physicians rely heavily on labs to deliver crucial hematology data reliably. Traditionally, hematology testing is a complex, time-sensitive process that necessitates skilled laboratory personnel to evaluate results before they can be relayed to physicians. The widespread use of CBC testing and escalating staff shortages can impact a lab's capacity to quickly review and release patients' test results. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers offer integrated automation and intelligence designed to overcome these challenges, thereby enhancing workflow efficiency and speeding up patient results delivery.

In hospital or critical care settings, the expected turnaround time for routine CBCs is typically less than an hour, while for STATs, it is ideally less than 10 minutes. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers can generate a throughput of up to 120 tests per hour. Their intuitive designs significantly decrease time-intensive daily maintenance while enabling quick reagent changes. Patients in critical condition, such as those with cancer, renal conditions, or neonates, require hematology testing to monitor their progress and guide adjustments to their care. Small changes in patient results can have significant implications if they are not flagged or if they are misinterpreted. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers incorporate advanced data management capabilities to address the expertise gap in labs, thus enabling staff of all skill levels to interpret results accurately.

The analyzers' rules-based auto-validation feature can release normal results—those that do not violate predefined criteria—directly into a laboratory information system, thereby saving time and enabling physicians to receive information more quickly. Any abnormalities are flagged and categorized by severity to clearly signify which patient samples need more detailed examination by a technician. When results necessitate further steps such as dilutions or slide reviews, standardized instructions can be displayed to ensure staff follows lab protocols. The Atellica HEMA 570 Analyzer measures 43 cell parameters, while the Atellica HEMA 580 Analyzer offers an additional 12 parameters, including indicators of immature red blood cells relevant to certain patient populations and an optical-based platelet count that reduces analytical interferences common in other detection technologies. Up to six Atellica HEMA 570 and Atellica HEMA 580 Analyzers can be integrated together to maximize throughput with intelligent, automated workload balancing and reflexive testing that minimizes operator involvement.

"We hear from labs that they need agility, reliability, and speed," said Sharon Bracken, Head of Diagnostics, Siemens Healthineers. "The Atellica HEMA analyzers combine workflow improvements with demonstrated technology to bring hematology testing into the future. We're delivering the breakthroughs labs need to produce quality patient results faster."

Related Links:
Siemens Healthineers 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.